2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
11
Phase 2
6
Phase 1/2
3
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Interventions
Cisplatin
725
Carboplatin
607
Paclitaxel
578
Cyclophosphamide
516
Radiotherapy
511
Docetaxel
475
Fluorouracil
453
Gemcitabine
437
Doxorubicin
383
Capecitabine
361
Dexamethasone
327
Oxaliplatin
288
pembrolizumab
283
Leucovorin
282
Bevacizumab
275
Etoposide
271
Vincristine
270
Rituximab
246
Prednisone
222
Pemetrexed
217
Cytarabine
205
Drug Therapy
194
Trastuzumab
175
Irinotecan
172
Methotrexate
171
Lenalidomide
137
Nivolumab
135
Filgrastim
135
Epirubicin
129
Tamoxifen
127
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
olaratumab
×
Clear all
NCT02451943
2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3
Completed
509 enrolled
23 charts